亚临床甲状腺功能障碍症增强了梅特福林在绝经后妇女中降低性腺激素的效果
Robert Krysiak1, Karolina Kowalcze2,3, Bogusław Okopień1
1Department of Internal Medicine and Clinical Pharmacology, Medical University of Silesia, Katowice, Poland.
Journal of clinical pharmacology
|October 4, 2024
概括
在患有甲状腺功能增强症的女性中,甲状腺素增强了对性腺激素的作用. 这项研究发现,尽管甲腺过度活跃,但甲胺在甲状腺轴上是中性的.
科学领域:
- 内分泌学 在内分泌学.
- 代谢障碍 代谢障碍 代谢障碍
- 生殖内分泌学 生殖内分泌学
背景情况:
- 众所周知,甲胺可以降低前垂体前垂体激素的升高水平.
- 亚临床甲状腺功能障碍可能会影响甲福尔对生殖激素的影响.
研究的目的:
- 为了研究甲状腺功能障碍是否调节甲福尔明对淋巴激素分泌的影响.
- 为了比较梅特福林在绝经后妇女的效果,有和没有亚临床甲状腺功能障碍.
主要方法:
- 一项前性队列研究,涉及48名患有2型糖尿病/糖尿病前期的绝经后妇女.
- 24名女性患有亚临床甲状腺功能障碍症,年龄,胰岛素敏感性和淋巴激素相匹配.
- 测试中的激素 (葡萄糖,胰岛素,TSH,甲状腺激素,FSH,LH等) 在基线和6个月的美特福林治疗期间.
主要成果:
- 甲胺改善了胰岛素敏感性 (HOMA1-IR),并且在高甲状腺女性中更显著地降低了FSH.
- 甲福明仅在甲状腺功能高的女性中降低了LH.
- 没有观察到TSH,甲状腺激素,雌激素,益生菌,ACTH或IGF-1的显著变化.
结论:
- 甲状腺功能障碍症增强了甲福林的淋巴激素降低作用.
- 在甲状腺功能障碍症中,甲福明似乎对下丘脑 - 下垂体 - 甲状腺轴具有中性的作用.
相关概念视频
Oral Hypoglycemic Agents: Biguanides and Glitazones
181
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
181
Menopause
143
Menopause, a natural biological process marking the end of a woman's fertility, typically occurs between the fifth and sixth decade of life. This phase is characterized by the exhaustion of the ovarian follicle pool, leading to less responsive ovaries despite the high levels of Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH). The consequential decrease in estrogen production results in symptoms like hot flashes, heavy sweating, headaches, hair loss, muscle pains, vaginal...
143
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
166
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
166
Hypoglycemia and Glucagon
206
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
206
Hormonal Regulation of the Menstrual Cycle
312
The ovarian cycle regulates endometrial changes throughout a single menstrual cycle via the coordinated action of gonadotrophin-releasing hormone (GnRH) and gonadotrophins.
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH...
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH...
312
Oral Hypoglycemic Agents: Sulfonylureas
195
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
195


